Acadian Asset Management LLC Has $4.24 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Acadian Asset Management LLC increased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 150.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,674,035 shares of the company’s stock after purchasing an additional 1,606,802 shares during the quarter. Acadian Asset Management LLC owned approximately 3.72% of Zentalis Pharmaceuticals worth $4,244,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in ZNTL. Millennium Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the period. Peapod Lane Capital LLC bought a new position in Zentalis Pharmaceuticals during the first quarter valued at approximately $888,000. Nuveen LLC bought a new position in Zentalis Pharmaceuticals during the first quarter valued at approximately $807,000. GSA Capital Partners LLP raised its position in Zentalis Pharmaceuticals by 275.9% during the first quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock valued at $862,000 after acquiring an additional 397,805 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in Zentalis Pharmaceuticals by 177.6% during the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after acquiring an additional 396,233 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $1.49 on Monday. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $1.01 and a fifty-two week high of $5.44. The firm’s fifty day moving average price is $1.52 and its two-hundred day moving average price is $1.47. The company has a market capitalization of $107.49 million, a P/E ratio of -0.66 and a beta of 1.76.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.19. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ZNTL. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Finally, HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.20.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.